Skip to main content
Image coming soon

HCE9932 Mastering Therapeutic Decision Points in Clinical Development

$199.00
Adding to cart… The item has been added

The Executive Diagnostic and Governance Toolkit

Mastering Therapeutic Decision Points in Clinical Development

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide whether to advance the lead therapeutic into late-stage trials based on interim efficacy data.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
The interim data is in. Now what? The pressure to advance a promising therapeutic must be balanced against the risk of failure in later studies.

The situation this is built for

Chief medical officers face one of the most consequential decisions in clinical development when reviewing interim efficacy results. There is no clear protocol for determining whether observed effects are sufficient to justify advancing a therapeutic. Teams rely on fragmented inputs—biostatistical outputs, site feedback, safety signals—without a unified framework to synthesize them. The absence of a structured decision model leads to prolonged debate, misalignment with executive leadership, and inconsistent thresholds across programs. The cost of getting it wrong is measured in wasted investment, delayed timelines, and erosion of credibility.

Who this is for

Chief medical officer at a clinical-stage medical technology company responsible for therapeutic development strategy and trial oversight

Who this is not for

This course is not for biostatisticians, regulatory specialists, or clinical operations managers. It is not for those focused on trial execution, data collection, or compliance documentation.

What you walk away with

  • Define defensible progression criteria for therapeutic advancement
  • Evaluate the clinical meaningfulness of interim efficacy signals
  • Lead go/no-go decision meetings with cross-functional alignment
  • Integrate safety, statistical, and operational data into a unified assessment
  • Anticipate regulatory expectations for pivotal trial design

How this maps to your situation

  • Assessing interim data quality
  • Evaluating clinical meaningfulness
  • Balancing benefit and risk
  • Leading organizational decision processes

Before vs. after

Before
You rely on fragmented inputs and subjective judgment to decide whether to advance a therapeutic, leading to inconsistent decisions and misaligned teams.
After
You apply a structured, evidence-based framework to evaluate interim results and lead decisive, defensible go/no-go discussions.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 3 hours per module, designed for integration into existing workflows with downloadable tools for immediate application.

If nothing changes
Without a rigorous decision process, organizations risk advancing therapeutics based on false signals or halting development due to excessive caution—both outcomes lead to wasted resources, delayed timelines, and erosion of stakeholder trust.

How this compares to the alternatives

Unlike general project management courses or statistical training programs, this course focuses exclusively on the clinical and strategic judgment required at therapeutic decision points, providing field-specific frameworks and templates used in actual development programs.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. Framing the Therapeutic Decision Challenge
Establish the scope and stakes of deciding whether to advance a therapeutic based on interim data.
12 chapters in this module
  1. Understanding the strategic weight of go/no-go decisions
  2. Identifying the key stakeholders in progression discussions
  3. Mapping the timeline from data readout to decision meeting
  4. Defining what constitutes a 'clinically meaningful' effect
  5. Differentiating signal detection from confirmatory evidence
  6. Recognizing the influence of organizational pressure on judgment
  7. Assessing the cost of false positive and false negative decisions
  8. Clarifying the distinction between efficacy and effectiveness
  9. Reviewing historical decisions to identify patterns and biases
  10. Documenting the rationale for future audit and alignment
  11. Aligning therapeutic potential with corporate development goals
  12. Setting expectations for data completeness at interim review
Module 2. Assessing the Quality of Interim Data
Develop a systematic method to evaluate whether interim results are reliable and representative.
12 chapters in this module
  1. Evaluating protocol adherence across clinical sites
  2. Identifying sources of selection bias in enrolled populations
  3. Assessing the consistency of endpoint measurement methods
  4. Reviewing the integrity of blinded data handling procedures
  5. Detecting early signs of data drift or outlier performance
  6. Validating the statistical analysis plan against actual execution
  7. Determining whether follow-up duration supports conclusions
  8. Checking for imbalances in baseline characteristics
  9. Assessing the impact of dropouts on observed outcomes
  10. Examining site-level variability in response rates
  11. Reviewing independent data monitoring committee commentary
  12. Confirming that stopping rules were appropriately applied
Module 3. Interpreting Efficacy Signals in Context
Move beyond p-values to assess whether observed effects are clinically relevant and sustainable.
12 chapters in this module
  1. Distinguishing statistical significance from clinical relevance
  2. Assessing magnitude of effect against minimal clinically important difference
  3. Evaluating response durability across timepoints
  4. Comparing observed outcomes to natural history data
  5. Benchmarking results against existing standard of care
  6. Analyzing subgroup responses for consistency and plausibility
  7. Evaluating the robustness of composite endpoints
  8. Assessing the risk of overfitting in exploratory analyses
  9. Interpreting confidence intervals as decision tools
  10. Weighing benefit in primary versus secondary endpoints
  11. Identifying patterns suggestive of placebo effect inflation
  12. Assessing convergence across multiple efficacy measures
Module 4. Integrating Safety and Tolerability Evidence
Balance efficacy signals with emerging safety data to inform risk-benefit assessment.
12 chapters in this module
  1. Mapping adverse event profiles across dose levels
  2. Assessing the severity and reversibility of safety signals
  3. Evaluating the consistency of lab abnormality patterns
  4. Identifying class-specific safety concerns
  5. Assessing the impact of concomitant medications
  6. Reviewing serious adverse event narratives for causality
  7. Determining whether safety events cluster in subgroups
  8. Weighing safety burden against observed benefit
  9. Assessing the adequacy of monitoring protocols
  10. Evaluating the potential for long-term safety risks
  11. Reviewing safety data from non-interventional cohorts
  12. Assessing whether safety profile supports future dosing strategy
Module 5. Modeling Probable Outcomes in Later Studies
Forecast the likelihood of success in confirmatory trials based on current evidence.
12 chapters in this module
  1. Estimating effect size attenuation in larger trials
  2. Assessing statistical power under realistic assumptions
  3. Modeling the impact of enrollment expansion on heterogeneity
  4. Predicting recruitment feasibility for next phase
  5. Evaluating the stability of endpoint definitions
  6. Assessing site performance scalability
  7. Forecasting dropout rates based on current trends
  8. Estimating resource needs for expanded operations
  9. Projecting regulatory requirements for submission
  10. Anticipating comparator performance in broader populations
  11. Modeling the impact of protocol amendments on outcomes
  12. Assessing the robustness of supply chain under increased demand
Module 6. Defining Go/No-Go Decision Criteria
Create explicit, pre-specified thresholds to guide objective therapeutic progression decisions.
12 chapters in this module
  1. Setting minimum efficacy thresholds for advancement
  2. Establishing safety tolerability boundaries
  3. Defining acceptable levels of statistical uncertainty
  4. Incorporating operational feasibility into criteria
  5. Aligning decision thresholds with regulatory precedents
  6. Balancing speed-to-market against evidence completeness
  7. Documenting exceptions to predefined criteria
  8. Involving regulatory advisors in threshold setting
  9. Requiring independent validation of key endpoints
  10. Setting thresholds for futility and early stopping
  11. Building flexibility for adaptive design considerations
  12. Requiring multidisciplinary sign-off on criteria
Module 7. Preparing for the Decision Meeting
Structure the presentation and discussion to ensure clarity, rigor, and alignment.
12 chapters in this module
  1. Designing a decision memo template for consistency
  2. Selecting the core data to present to leadership
  3. Anticipating key questions from executive stakeholders
  4. Preparing visualizations that clarify uncertainty
  5. Assigning roles for presenters and facilitators
  6. Incorporating independent data monitoring input
  7. Rehearsing responses to common objections
  8. Ensuring all functional areas submit position summaries
  9. Distributing materials with sufficient lead time
  10. Building consensus before the formal meeting
  11. Identifying potential dealbreakers in advance
  12. Establishing rules of engagement for debate
Module 8. Leading the Go/No-Go Discussion
Facilitate a high-stakes conversation with clarity, neutrality, and decisiveness.
12 chapters in this module
  1. Opening the meeting with decision framework recap
  2. Presenting efficacy evidence with context and caveats
  3. Integrating safety findings into the narrative
  4. Highlighting areas of data uncertainty
  5. Managing emotional responses to ambiguous results
  6. Addressing commercial enthusiasm with clinical rigor
  7. Challenging assumptions behind optimistic projections
  8. Ensuring all voices are heard in deliberation
  9. Clarifying the difference between risk and uncertainty
  10. Maintaining focus on predefined decision criteria
  11. Navigating pressure from investors or partners
  12. Summarizing positions before calling for resolution
Module 9. Documenting the Decision and Rationale
Create a permanent, auditable record that supports future decisions and regulatory review.
12 chapters in this module
  1. Writing a decision rationale statement with precision
  2. Archiving supporting data and analyses
  3. Capturing dissenting opinions and minority views
  4. Linking the decision to predefined criteria
  5. Recording assumptions about future trial design
  6. Noting conditions for revisiting the decision
  7. Ensuring regulatory team concurrence on language
  8. Storing documentation in compliant systems
  9. Generating a summary for board-level communication
  10. Updating development timelines based on outcome
  11. Flagging dependencies for operational teams
  12. Scheduling follow-up review for delayed decisions
Module 10. Executing the Next Steps After Decision
Translate the decision into actionable plans for trial teams and external partners.
12 chapters in this module
  1. Issuing formal notification to trial sites
  2. Updating clinical trial registry entries
  3. Informing data monitoring committees of outcome
  4. Adjusting drug supply and distribution plans
  5. Revising investigator brochures as needed
  6. Updating statistical analysis plans for next phase
  7. Communicating with contract research organizations
  8. Reallocating budget and headcount resources
  9. Initiating protocol development for confirmatory study
  10. Preparing briefing materials for regulatory meetings
  11. Updating intellectual property strategy based on outcome
  12. Notifying collaborating institutions and partners
Module 11. Learning from Past Decisions
Build institutional memory by reviewing past go/no-go choices and their outcomes.
12 chapters in this module
  1. Conducting retrospective analysis of prior decisions
  2. Comparing predictions to actual trial outcomes
  3. Identifying cognitive biases in historical deliberations
  4. Updating decision criteria based on experience
  5. Archiving decision rationales for future reference
  6. Interviewing past participants for process feedback
  7. Measuring alignment between prediction and result
  8. Assessing the impact of external pressures
  9. Evaluating the clarity of documented rationale
  10. Tracking evolution of decision-making standards
  11. Incorporating regulatory feedback into review
  12. Sharing insights across therapeutic programs
Module 12. Building a Repeatable Decision Framework
Institutionalize a rigorous, adaptable process for future therapeutic decisions.
12 chapters in this module
  1. Standardizing go/no-go criteria across portfolios
  2. Creating templates for decision memos and presentations
  3. Training medical leaders in decision methodology
  4. Integrating framework into governance calendars
  5. Automating data collection for decision inputs
  6. Establishing review cycles for criteria updates
  7. Linking decision framework to portfolio strategy
  8. Requiring framework use in all therapeutic reviews
  9. Auditing adherence to decision process
  10. Soliciting external expert validation
  11. Benchmarking against industry practices
  12. Measuring decision quality over time

Frequently asked

Who is this course designed for?
This course is designed for chief medical officers responsible for making or advising on therapeutic progression decisions based on interim clinical data.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Does this course cover statistical methods in depth?
The course assumes foundational knowledge of biostatistics and focuses on the interpretation of results within clinical and strategic contexts rather than computational techniques.
Can the frameworks be applied across therapeutic areas?
Yes, the decision structure is designed to be adaptable to oncology, neurology, immunology, and other domains based on disease-specific endpoints and risk profiles.
Is there a live component or facilitation?
No, the course is entirely self-paced and text-based, with practical tools designed for immediate use in real-world decision settings.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 3 hours per module, designed for integration into existing workflows with downloadable tools for immediate application..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.